Cite
MLA Citation
Mark Robson et al.. “Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.” European journal of cancer, vol. 120, 2019, pp. 20–30. http://access.bl.uk/ark:/81055/vdc_100092536323.0x000038